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Introduction
The EANM 2003 Congress-President, Prof. P.P. van Rijk in his
EJNM congress issue wrote: “ the main theme of the EANM 2003
congress is quality. This is very evident in all the components
of the meeting, including plenary sessions, continuing medical
education, expert opinion lectures and the industrial exhibition”.
He was right. The organisation was close to, if not, perfect.
Everything operated like the mechanism in a Swiss watch: smooth
and on time.
The aim of this lecture is not to summarise all the events
— more experienced people would do that better. We would like
to show the participation of Central and Eastern European Societies
of Nuclear Medicine in this Congress.
Committees/Chairs
Of 12 members of the Scientific EANM 2003 Committee, two
were from CEE countries: L. Pavics from Hungary (Chief Reviewer
— Radiopharmacy) and P. Lass from Poland (Chief Reviewer
— Neurology/Psychiatry). Mr. Z. Petrovic from Slovenia was
a member of the Technologists Program Committee.
Ten people chaired the sessions: K. Borbely (Hungary), J. Fet-
tich (Slovenia), S. Illic (Serbia), G. Janoki (Hungary), P. Lass (Po-
land), M. Myslivecek (Hungary), L. Pavics (Hungary), T. Stopar
(Slovenia), I. Szilvasi (Hungary). Z. Petrovic (Slovenia) chaired tech-
nologists session.
Industrial exhibition
Four commercial companies from CEE had their own booths
during the Congress; three radiopharmaceutical companies and
one gamma-cameras producer: Lacomed Ltd. (Rez, Czech Re-
public), The Institute of Isotopes and MEDISO Medical Imag-
ing Systems (Budapest, Hungary), Radioisotope Centre Pola-
tom (Otwock, Poland). The biggest and most impressive was
the Hungarian booth. At the Lacomed booth an interesting pro-
motion of new nuclear medicine atlases was held, as a conti-
nuation of a well-organised education action.
Scientific contribution
At this Congress a total 1252 papers were presented: 431 in
oral sessions and 821 in poster sessions. In total 29 papers in oral
sessions and 107 in poster sessions originated in Central and
Eastern Europe. The distribution of these papers is presented in
Table 1.
If we examine this table, both the CEE participation in EANM
presentations and their geographical distribution remains little
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Table 1. Papers from CEE countries
Country Oral Poster Total
presentations  presentations
Poland 13 20 33
Hungary 6 15 21
Serbia & Montenegro 4 14 18
Russia 2 13 15
Slovenia 2 9 11
Croatia 2 5 7
Czech Republic 16 16
Bulgaria 7 7
Ukraine 4 4
Romania 2 2
Bosnia & Herzegovina 1 1
Slovakia 1 1
Total 29 107 136
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changed in comparison to the previous Congresses. The total
amount of presentations stayed at the level of about 11%, a little
less in oral presentations, a little more in posters. As usual the
highest number of papers was from Poland, Hungary and Czech
Republic, a little less than usual from Russia and more than
previously from Slovenia. A continuous increase in the number
of presentations came from Serbia, Bulgaria and Ukraine.
Presentations overview
Cardiology
Teresińska et al. (Warsaw, Poland) presented their studies on
123I-MIBG monitoring of transmyocardial laser therapy, showing
the reduction in the activity of the cardiac adrenergic system
(O 135). The other interesting study on 123I-MIBG cardiac applica-
tion in patients after heart transplantation came from Ljubljana,
Slovenia by Milcinski et al. (O 136), and another one on cardiac
123J-MIBG scanning in hypertensive and cardiomyopathic patients
by Sergienko (Moscow, Russia, P 70).
Szilvasi et al. (Budapest, Hungary) showed that nitroglyceri-
ne-augmented 99mTc-Tetrofosmin myocardial scintigraphy is not
a substitute for rest 201Tl-201 scintigraphy (O 166). The issue
of nitroglycerine injection and gated SPECT has been also stu-
died by Kobylecka et al. (Warsaw, Poland) showing a segmental
decrease in MIBI uptake, but not a decrease in LVEF (P 3).
Kostkiewicz et al. (Cracow, Poland) compared Coronary
Artery Calcium Score and multi-slice computer tomography con-
cluding that CACS could be used as a screening tool for risk strat-
ification (O 246).
An interesting multi-centre study came from Prague, Olomouc
and Rez in Czech Republic on 201Tl versus 18FDG PET in myocar-
dial viability assessment. They suggest that the performance
of 201Tl scanning is so good that it should be used as a test prior to
FDG scanning, referring to PET scanning only those patients with
a non-viable myocardium (P 62).
A contribution to the discussion in the long-running saga on
the stress-test versus the dipyridamole test came from Zajecar
(Serbia) by Mitov et al., advocating the safety of the latter. Foel-
des (Budapest, Hungary) studied the influence of dipyridamole
on organ distribution of MIBI, as well as DTPA and anti-CEA anti-
bodies in rabbits (P 90).
Garai et al. (Budapest, Hungary) raised an interesting question
of patients’ preparation for CABG. They proposed 99mTc-HSA hand
perfusion scanning for the safe removal of a radial artery graft (P 75).
Oncology
A significant number of papers were devoted to oncology.
A number of presentations were devoted to peptides. Hu-
balewska and colleagues from Cracow (Poland) presented an in-
teresting comparison of 99mTc-Hynic-EDDA-TATE somatostatin
receptors ligand and 111In-octreoscan in tumour imaging (O 39).
Technetium radiopharmaceutical seems to be both a cheaper and
a promising ligand. The sceptical voice came from Budapest, Hun-
gary, where Szilvasi et al. showed that octreotide scanning is not
cost-effective in incidentally found gastrointestinal carcinoid (P 192).
Cholewiński et al from Lublin (Poland) showed the usefulness
of 99mTc-depreotide in children’s lymphoma (O 223). A paper by
Belohlavek et al. from Prague, Czech Republic also referred to
paediatric oncology, studying the impact of FDG PET on the thera-
peutic management of children with solid tumours (P 140). About
one third of those results changed the course of therapy.
The significant impact of PET on patient management has been
also shown in a paper by Makaiova and co-workers from Bratislava,
Slovakia (P 139).
Myslivecek and colleagues (Olomouc, Czech Republic) un-
derlined the role of 99mTc-MIBI scanning in the prognosis and fol-
low-up of multiple myeloma (P 197).
An issue of increasing importance is sentinel node imaging.
Hubalewska and co-workers from Cracow (Poland) studied
a set of lymphoscintigraphies in cervical cancer, which is a rela-
tively new and important issue in gynaecology (O 412), with prom-
ising results. Koranda et al. (Olomouc, Czech Republic, described
the same issue in endometrial cancer (P 724). Kafka et al from
Hradec Kralove, Czech Republic proposed 99mTc-labelled dextran
as a sentinel node imaging tracer (P 37). A technical mammary
sentinel node radiolocalisation paper on breast cancer was given
by a group by Rajtar et al from Budapest, Hungary (P 735).
A high percentage of lymph node unspecific binding in a 99mTc-
-AntiCEA Antibody immunolymphoscintigraphy paper came from a
group of Foeldes from Budapest, Hungary (P 740). Gastric and co-
lon lymphoscintigraphy intra-operative nanocolloid scintigraphy re-
sults were presented by Hubalewska and colleagues from Cracow,
Poland (P 741). One could ask the question whether their first con-
clusion that “SN metastases in gastric and colorectal cancer can be
detected by preoperative lymphoscintigraphy...” is too far reaching.
Some papers were devoted to scintimammography. A group
from Russia, Serbia and Italy studied the kinetics of 99mTc-HMPAO
uptake in breast tumours (P 226). They propose this tracer as
a marker of tumoral and lymph node blood flow. A tetrofosmin/
/MIBI scintimmamography studies came also from Sofia (Bulgaria)
and Sremska Kamenica (Serbia — P 234, P 242).
Regarding radionuclide therapy, an interesting but, to me,
slightly controversial paper came from Sofia, Bulgaria. Kostadi-
nova and co-workers strongly advocate phosphorus-32 as a bone
metastases treatment agent for its much lower price. This is an
approach which one comes across today here and there, even on
the pages of JNM/NMC; however, I would be cautious.
Endocrinology
Endocrinology is still an important issue in nuclear medicine,
although the role of cardiac and oncologic studies is continuously
increasing.
Many papers were devoted to 131J therapy, both of hyperthyre-
osis and cancer.
Parfieńczyk and co-workers (Bialystok, Poland) presented an
interesting paper on apoptotic markers following 131J-therapy
(O 66). Listewnik et al. (Szczecin, Poland) underlined the role
of thyroid volume measurement in 131J Graves’ disease therapy,
showing the lower effectiveness of therapy in large thyroid volume
(O3 43). Galuska et al. from Debrecen (Hungary) advocated
the 99mTc-DTPA-SPECT in the assessment of Graves’ orbithop-
athy (O 347). An interesting model of calculating the functioning
volume of autonomous thyroid nodules calculated from scinti-
graphic data using the geometric method, has been proposed by
Foeldes et al., Budapest, Hungary (P 512). An interesting model
of calculating dosimetry in benign and malignant thyroid diseases
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came from Medvedec and Dodig (Zagreb, Croatia).
Balenovic and colleagues from Zagreb (Croatia) analyzed
the course of pregnancy in women after 131J-therapy of thyroid carci-
noma. They believe that after an interval of 1 year post therapy there
is no reason to discourage women from becoming pregnant (O 348).
The effects of 131J thyroid cancer therapy were discussed in
two posters from Institute of Oncology, Sremska Kamenica, Ser-
bia (P 468, P 473), and in three posters on thyroid self-stunning
(P 467) and on thyroid remnants ablation (P 469, P 470) from
The Institute of Oncology, Kiev, Ukraine.
An interesting poster came from Cluj-Napoca, Romania on
thyroid tumours of non-thyroid origin (P 586).
A number of papers were focused on parathyroid imaging.
Szilvasi and co-workers analysed the usefulness of tetofosmin and
sestamibi in parathyroid imaging. While showing a similar reten-
tion, they showed a higher sestamibi wash-out, therefore advo-
cating the latter tracer (O 185). A similar paper came from Szeged,
Hungary by Besenyi et al. (P 579). Rep et al. (Ljubljana, Slovenia)
advocated the use of parathyroid SPECT when compared to the
two-tracer wash-out technique (T 14). Kobylecka et al. from War-
saw (Poland) presented a paper on semiquantitative 99mTc-MIBI
washout in parathyroid adenomas (O 61). From the same group,
a paper came showing no prolonged MIBI uptake in the majority
of parathyroid adenomas (O 179), a paper analysing the useful-
ness of intra-operative gamma probe in primary hyperthyroidism
(O 184), as well as a comparative study with ultrasound (P578).
Dabasi et al. from Budapest (Hungary) presented a paper on in-
tra-operative parathyroid hormone monitoring in secondary
hyperparathyroidism (O 172).
Neurology
In a simple, but very elegant study Borbely et al (Budapest,
Hungary) studied the plasticity of language networks by speech-
-activation SPECT in patients post brain-tumour operations.
She showed a diversified increase of rCBF showing the undertaking
of speech function by diverse brain areas post-operation (O 234).
The other neuroactivation study came from Varna, Bulgaria,
where Klissarova et al. found no influence of neuroactivation on
CBF in vascular dementia, but a positive effect in AD (P 284).
Gornostaev and colleagues from Moscow, Russia found
a reduced cerebrovascular reserve in patients with arterial hyper-
tension and metabolic syndrome (P 38). Cerebrovascular reserve
in patients pre- and post carotid endarterectomy were studied by
Garai (Budapest, Hungary). Utilising the acetazolamide stress-
test they showed that endarterectomy does not improve post-op
cerebrovascular reserve (P 275). Lishmanov and colleagues (Tomsk,
Russia) analysed brain perfusion and the circadian rhythm of ar-
terial pressure in hypertensive patients. They showed decreased
CBF and cerebrovascular decrease in those patients, even if fo-
cal neurological symptoms were absent (P 281). Petrovic and
co-workers from Zagreb, Croatia found significant asymmetries
in ventral basal ganglia in Croatian war veterans with severe hy-
perarousal symptoms (P 304). In two posters also from Zagreb
Crnkovic et al. studied CBF changes in schizophrenic patients
treated with haloperidol and risperidone (P306 and P 309).
Brain SPECT studies were also applied is assessing the phar-
macotherapy of depression, using 99mTc-TRODAT (Argyelan et al.,
Budapest, Hungary, P 326).
GI tract/Urinary tract/kidneys
Stępień and colleagues from Cracow, Poland studied
oesophagus motility in systemic sclerosis. Frankly speaking, this
is a rather old issue, but this paper had some pathophysiologic
merit (P 555). Artiko et al. from Belgrade, Serbia evaluated liver
transplant function using hepatic radionuclide angiography and
hepatobiliary scintigraphy (P 604). From the same group a paper
came on 99mTc-ciprofloxacin for the detection of abdominal and
GI infections. Sinikin and co-workers (Tomsk, Russia) used biliary
scintigraphy for the follow-up of jejunogastroplasty. A group led
by Surma et al. from Łódź, Poland analysed the usefulness of
99mTc-HEPIDA hepatic and plasma clearance in the assessment of
liver parenchyma performance (P 610). Three papers on gastric
emptying came from Ajdinovic et al. and Obradovic et al. from Bel-
grade, Serbia (P 654 and P 661) and Klissarova et al., Varna, Bul-
garia (P 660). Buncova et al. used 67Ga for gastrointestinal transit
(P672). Why gallium?
A group from Belgrade (Serbia), Jaksic et al. discussed
the role of 99mTc-p-aminohippuric acid as the new renal agent
(O 104). A group from Niš, Serbia (Vlajkovic et al.) was traditional-
ly focused on VU reflux studies (P 682).
Infection and inflammation
Planar and SPECT imaging of orthopaedic infections using
99mTc-ciprofloxacin was proposed by Obradovic et al. from Bel-
grade (Serbia).
Joints/Varia
An interesting series of three papers on holmium-166 in
synoviorthesis was presented by a group of Szentesi et al. from
Budapest, Hungary (P 498, P 499, P 500). In one experiment
(on rabbits) and two clinical studies they concluded that  166Ho is
highly useful, probably less damaging than 90Y, 169Er or 186Re as
well as being  suitable for large and medium-sized joints.
Andrysiak and colleagues (Warsaw, Poland) described
the progression of joints 99mTc-IgG uptake despite clinical improve-
ment with a good correlation with MRI findings. I wish I had such
a strong belief in 99mTc-IgG.
Two papers on hip necrosis came from Slovenia. Milcinski
et al. from Lubljana advocated the assessment of marginal zone
in femoral hip necrosis scanning as a prognostic factor (P 760),
Predic from Celje compared three-phase hip scanning with X-ray
and MRI scanning (P 767).
Two posters were about thrombocytopenia. Nikolova et al.
(Sofia, Bulgaria) advocated the role of 111In labelled platelets in
differential diagnosis, they can differentiate initial stage of hyper-
splenism from ATP when laboratory findings are identical (P 799).
Todorovic-Tirnanic et al. from Belgrade, Serbia has carried on her
earlier studies, advocating in vivo kinetics of 111In labelled plate-
lets as an important quality control parameter (P 803).
Radiopharmacy/Radiochemistry
Garnuszek et al. from Warsaw, Poland, proposed water-solu-
ble radioactive platinum(IV) complexes as a potential carrier in
RN therapy (O 365 and O 369). A group of Mirowski and col-
leagues (Łódż, Poland) studied opioid receptors radioligands in
mammary carcinoma (P 339). Krasikova et al. (Moscow, Russia,
P 357) studied the properties of 18F labelled tyrosine as a promi-
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sing PET tumour imaging agent. Two papers from POLATOM,
Otwock, Poland were devoted to infection/inflammation imaging:
the first on 99mTc-HIG l with, the second on 99mTc-ciprofloxacin dis-
tribution in rats (P 380, P 383).
Three interesting papers in therapeutic radiopharmacy came
from Czech Republic. Kopecky and co-workers analysed
90Y-DOTA-Tyr3 -octreotate renal uptake in rats (P 388). Kropacek
et al. described the preparation of 166Ho polylactic acid for liver
tumour therapy (P 391). Laznicek et al analyzed the effect of re-
ceptor-specific binding on the distribution and elimination
of 90Y-DOTA-Tyr3 -octreotate in rats (P 533).
Instrumentation and physics
Bosnjakovic (Belgrade, Serbia) presented a paper on the ap-
plication of LaBr3 (Ce
3+) as a basis of new scintillation detectors
and new cost-effective dual-head gamma-cameras (O 114).
Three interesting papers came from the Institute of Medical
Informatics (Warsaw, Poland) by Owczarczyk and colleagues
(O 156, P 423, P 455). They focused on brain SPECT data quantifi-
cation using  the Talairach space, the 3D visualisation in template-
based quantification of brain perfusion SPECT and compensating
for detector response and attenuation in SPECT using the iterative
BI-SMART algorithm. If they manage to develop this software in
practice, this might be a promising alternative to the very good, but
very expensive Nuclear Diagnostic AB (HERMES) solutions.
A paper on the application of the artificial neural network algo-
rithm for parathyroid adenoma detection came from Stefaniak et al.,
from Lublin, Poland (P 420).
An interesting paper on MRI/SPECT image fusion in gliomas came
also from Łódź, Poland (P 212) by M.R. Górska-Chrząstek et al.
Medved and co-workers, Zagreb, Croatia, developed an effi-
cient, low-cost telemedicine software for nuclear medicine (P 807).
Radioprotection
Medvedec and Dodig (Zagreb, Croatia) compared the use
of uncollimated gammacameras vs the dedicated whole-body-
counter. They concluded that the use of uncollimated gamma-
cameras, especially in wider-scale accidents is possible and jus-
tified, however a great attention should be paid to calibration
methodology (O 284).
Concluding remarks
Analysing the comments made above, three types of remarks
can be discerned: those which are favourable, warnings or disap-
provals. It is good that Central European countries are increa-
singly having a visible input into the European nuclear medicine
community; the participation of CE countries, measured by the
number of presentations as compared with EANM Congress’97
increased from 7 to 11% of all contributions. The good news is
that domestic radiopharmaceutical companies survived and still
play a significant role in supporting research projects. More good
news is also that the number of PET units in CEE countries has
increased from 1 to 6, although, as seen above, their scientific
role could be bigger.
CEE countries, or at least some of them, should be wary
of increasingly losing contact with the leading European NM centres.
And if good ideas still matter, even with old equipment, the question
of how long this can continue has to be asked. This is the challenge
for us and for the nuclear medicine community in a uniting Europe.
